Role of SARS-CoV-2 in Asthma Exacerbations

Öztürk, Ayşe Bilge; Bavbek, Sevim

doi:10.21911/aai.560

Cited by 2 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 Nevertheless, we know from prior global experiences with viruses that well-controlled asthma patients are less susceptible to exacerbations during acute infections. 2,12 Th2 high inflammation, inhaled steroid use, ACE receptor gene downregulation, and good asthma control may all have an impact on better outcomes of COVID-19 patients with asthma.…”

Section: Overall Does Asthma Increase Covid-19 Risk or Worsen The Out...mentioning

confidence: 99%

“…From what we know so far, allergic airway diseases can be triggered by respiratory pathogens, which leads to persistent airway symptoms even after the clearance of the infection. 2 To give a solid example from influenza, people with asthma tend to develop asthmatic exacerbations and recover late from the virus. Current evidence suggests that this might not be the entire picture with COVID-19.…”

Section: Introductionmentioning

confidence: 99%

“…Current evidence suggests that this might not be the entire picture with COVID-19. 2 Asthma to this day is listed with other pulmonary diseases as a comorbid risk factor for severe outcomes. This was first questioned because of the underrepresentation of asthma among patients hospitalized with severe disease in different cohorts around the world.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome

Sönmez¹,

Kısakürek²,

Öztürk³

et al. 2021

Turk Thorac J

View full text Add to dashboard Cite

Recent developments in research have put forward claims on the protective effect of allergic diseases-especially allergic airway inflammation including allergic asthma-against the COVID-19 pandemic. This was first suggested by the underrepresentation of asthma patients in some cohorts and was later investigated by angiotensin-converting enzyme II (ACEII) receptor expression studies. Controversial data on this matter persists and continue to be a challenge for clinicians when it comes to managing allergic diseases during the pandemic. We present in this study a thorough review of related findings so far and our own experience with 2 severe asthma patients who presented with atypical symptoms. Interestingly, both patients were administered anti-IgE therapy prior to the initial positive polymerase chain reaction (PCR) results for COVID-19 and showed no symptoms of severe respiratory disease during the infection unlike what we know from other viral respiratory illnesses. Stemming from that, we wanted to combine the perspectives of allergists and infectious disease specialists to address certain concerns in the management of allergic diseases, such as biologicals, in the light of current guidelines. We have also pointed out certain gaps in clinical and molecular level research, such as the lack of phenotypical subgroup analysis among ill asthma patients and the lack of data concerning the molecular effects of biologicals on viral infection.

show abstract

Section: Overall Does Asthma Increase Covid-19 Risk or Worsen The Out...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome

Sönmez¹,

Kısakürek²,

Öztürk³

et al. 2021

Turk Thorac J

View full text Add to dashboard Cite

show abstract

“…Furthermore, these factors have led to SARS-CoV-2-related fear, worry and anxiety in patients (6). Patients with severe asthma are at particularly higher risk for SARS-CoV-2 infection due to exacerbations of asthma caused by viral infections, increased SARS-CoV-2 viral load at hospitals and challenges in access to healthcare facilities due to several restric¬tions (7)(8)(9). However, it has been revealed out that many patients hindered their treatments or did not present asthma outpatient clinics and that they, therefore, did not receive particularly their monoclonal antibody therapy due to the restrictions imposed during this period and fear of SARS-CoV-2 infection.…”

Section: Introductionmentioning

confidence: 99%

Effect of the SARS-CoV-2 pandemic on treatment processes of patients with severe asthma who were managed with monoclonal antibody

Atayık

Aytekin

2022

Hitit Medical Journal

View full text Add to dashboard Cite

Background: Patients with severe asthma are at particularly higher risk for SARS-CoV-2 infection due to exacerbations of asthma caused by viral infections, SARS-CoV-2 viral load at hospitals and challenges in access to healthcare facilities due to some restrictions. Thus, we aimed to investigate effect of the SARS-CoV-2 pandemic on treatment and control of asthma in patients receiving monoclonal antibody MAb treatment. Methods: The patients, who were using MAb for treatment of for severe persistent asthma, were enrolled. Each patient was asked to fill in a validated Coronavirus anxiety scale and a mini survey. Results: Sixty-two patients (Female: 44; Male: 18), who were given MAb therapy for asthma, were enrolled. Patients’ treatment compliance was 56.5% in March-April-May 2020. Curfew was the most common government-related factors that have influenced patients’ compliance to treatment (35.5%). The most common individual factor was fear of contracting SARS-CoV-2 (40.3%). Exacerbated symptoms and need for additional treatment for asthma were significantly more common in patients, who were not compliant to treatment, compared to the patients adherent to MAb treatment (p: 0.034 and p:0.013) Conclusion: Treatment compliance has reduced in patients, who take MAb treatment, due to both governmental and individual reasons. This has led to more common admissions to emergency department with complaints of asthma and need for an additional treatment. All these findings indicate that patients should maintain their MAb treatments despite the pandemic and that they should minimize the risk of SARS-CoV-2 infection by following the recommendations published in the guidelines.

show abstract

Role of SARS-CoV-2 in Asthma Exacerbations

Cited by 2 publications

References 16 publications

COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome

COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome

Effect of the SARS-CoV-2 pandemic on treatment processes of patients with severe asthma who were managed with monoclonal antibody

Contact Info

Product

Resources

About